Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy
Authors
Mathilde Bastien•Maxime Jullien•Patrice Chevallier
Journal
Blood
Published
November 5, 2024
Sign in to review
Share your thoughts on this paper...
Supporters
Support the authors with ResearchCoin
Topics
DOI
License
Unknown License
No reviews yet.
Be the first to review this paper.